The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
JAK/STAT 通路在系统性硬化症中被激活，托法替尼可有效靶向该通路
阅读：6
作者：Wenxia Wang, Swati Bhattacharyya, Roberta Goncalves Marangoni, Mary Carns, Kathleen Dennis-Aren, Anjana Yeldandi, Jun Wei, John Varga
Conclusion
These findings implicate the JAK/STAT pathway in systemic sclerosis skin and lung fibrosis and identify tofacitinib as a potential antifibrotic agent for the treatment of systemic sclerosis and other fibrotic diseases.
Methods
Bioinformatic analysis showed that IL6/JAK/STAT3 and tofacitinib gene signatures were aberrant in biopsies from systemic sclerosis patients in four independent cohorts. The
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。
2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。
4、投稿及合作请联系：info@biocloudy.com。
